{"schema_version":"secwatch.filing_event.v1","accession":"0000896622-25-000004","form_type":"8-K","ticker":"ATR","cik":"0000896622","company_name":"APTARGROUP, INC.","filed_at":"2025-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.733532+00:00","generated_at":"2026-05-27T02:12:32.361905+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AptarGroup Q4 net income +62% to $101M; adj. EPS $1.52; pharma sales +8% FY","bullets":["Q4 reported EPS $1.49 (+60% YoY); adjusted EPS $1.52 (+27% YoY).","Full-year net income $375M (+32%); adjusted EPS $5.64 (+18%).","Pharma core sales +4% Q4; Closures core +7% Q4; Beauty core -3% Q4.","Q1 2025 adj. EPS guidance $1.11-$1.19; currency headwind ~$0.07; tax rate 25-27%.","Board authorized $500M share repurchase; quarterly dividend $0.45/share declared."],"urls":{"canonical":"https://secwatch.observer/filing/0000896622-25-000004","json":"https://secwatch.observer/filing/0000896622-25-000004.json","markdown":"https://secwatch.observer/filing/0000896622-25-000004.md","text":"https://secwatch.observer/filing/0000896622-25-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896622/000089662225000004/0000896622-25-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896622/000089662225000004/atr-20250206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T02:12:32.361905+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}